Therapeutic Targeting of the Proteasome in Disease

In honor of Julian Adams, Ph.D., Kenneth C. Anderson M.D., Alfred L. Goldberg, Ph.D. , and Paul G. Richardson, M.D. for their discovery, preclinical and clinical development of Bortezomib (Velcade) to FDA approval and front line therapy for the treatment of patients with multiple myeloma.

Program

Opening Remarks

Jeffrey S. Flier, MD, Dean of the Faculty of Medicine, Harvard University

Joan S. Brugge, PhD, Louise Foote Pfeiffer Professor of Cell Biology and Chair of the Department of Cell Biology, Harvard Medical School

Alfred L. Goldberg, PhD, Professor of Cell Biology, Harvard Medical School Functions of the Proteasome: From Protein Degradation to Drug Development

Julian Adams, PhD, President, Research and Development, Infinity Pharmaceuticals The Discovery and Development of Bortezomib

Kenneth C. Anderson, MD, Kraft Family Professor of Medicine, Harvard Medical School, Director of the LeBow Institute for Myeloma Therapeutics and Director of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute Bench to Bedside Translation of Proteasome Inhibitor Therapy in Multiple Myeloma

Paul G. Richardson, MD, Associate Professor of Medicine, Harvard Medical School and Clinical Director of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute The Clinical Development of Bortezomib in Multiple Myeloma: from Single Agent to Combinations and Beyond